Biocryst Drug Patent Portfolio
Biocryst owns 2 orange book drugs protected by 12 US patents Given below is the list of Biocryst's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662160 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US11117867 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US11618733 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US10125102 | Human plasma kallikrein inhibitors | 07 Apr, 2035 | Active |
| US10329260 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US10689346 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US11230530 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US11708333 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US8778997 | Antiviral treatments | 07 May, 2027 | Active |
| US10391075 | Antiviral treatments | 12 Feb, 2027 | Active |
| US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors | 16 Dec, 2023 | Expired |
| US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus | 05 Nov, 2019 | Expired |
Latest Legal Activities on Biocryst's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biocryst.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Nov, 2023 | US10689346 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Nov, 2023 | US10662160 |
| Patent eGrant Notification | 25 Jul, 2023 | US11708333 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 25 Jul, 2023 | US11708333 |
| Mail Patent eGrant Notification | 25 Jul, 2023 | US11708333 |
|
Email Notification
Critical
| 25 Jul, 2023 | US11708333 |
| Recordation of Patent eGrant | 25 Jul, 2023 | US11708333 |
|
Recordation of Patent Grant Mailed
Critical
| 25 Jul, 2023 | US11708333 |
|
Electronic Review
Critical
| 25 Jul, 2023 | US11708333 |
|
Email Notification
Critical
| 06 Jul, 2023 | US11708333 |
|
Electronic Review
Critical
| 06 Jul, 2023 | US11708333 |
|
Issue Notification Mailed
Critical
| 05 Jul, 2023 | US11708333 |
| Dispatch to FDC | 09 Jun, 2023 | US11708333 |
|
Application Is Considered Ready for Issue
Critical
| 09 Jun, 2023 | US11708333 |
|
Issue Fee Payment Verified
Critical
| 18 Apr, 2023 | US11708333 |
Biocryst's Family Patents
Biocryst Drug List
Given below is the complete list of Biocryst's drugs and the patents protecting them.
1. Orladeyo
Orladeyo is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662160 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(14 years from now)
| Active |
| US11117867 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(14 years from now)
| Active |
| US11618733 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(14 years from now)
| Active |
| US10125102 | Human plasma kallikrein inhibitors |
07 Apr, 2035
(10 years from now)
| Active |
| US10329260 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(10 years from now)
| Active |
| US10689346 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(10 years from now)
| Active |
| US11230530 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(10 years from now)
| Active |
| US11708333 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orladeyo's drug page
2. Rapivab
Rapivab is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8778997 | Antiviral treatments |
07 May, 2027
(2 years from now)
| Active |
| US10391075 | Antiviral treatments |
12 Feb, 2027
(2 years from now)
| Active |
| US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
16 Dec, 2023
(10 months ago)
| Expired |
| US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
05 Nov, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapivab's drug page